Advertisement Neuroptix names new COO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Neuroptix names new COO

Neuroptix, a developer of non-invasive and predictive laser eye scanning test for the early detection and diagnosis of Alzheimer's disease, has named Gerald Cagle as its new COO.

Most recently, Dr Cagle has served as senior vice president of R&D and chief scientific officer of Alcon Laboratories, a subsidiary of Alcon, Inc, an eye care company.

Dr Cagle has received his bachelor of science degree from Wayland College in Plainview, Texas. Dr Cagle earned both a master of science and a PhD from the University of North Texas in Denton, Texas.

Paul Hartung, president and CEO of Neuroptix, said: “We are delighted to have an industry veteran of Gerald Cagle’s caliber as part of our executive leadership at Neuroptix.

“He brings a wealth of industry experience of direct relevance to our mission of providing a new and reliable ocular-based diagnostic test for Alzheimer’s, and we look forward to his leadership as we bring our Sapphire technology toward clinical trials.”